Open Access Research article

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study

Marit Synnestvedt1, Elin Borgen2, Erik Wist113, Gro Wiedswang4, Kjetil Weyde5, Terje Risberg6, Christian Kersten7, Ingvil Mjaaland8, Lise Vindi9, Cecilie Schirmer2, Jahn Martin Nesland10 and Bjørn Naume11*

Author Affiliations

1 Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

2 Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

3 Department of Oncology, Oslo University Hospital, Ullevål, Oslo, Norway

4 Department of Surgery, Oslo University Hospital, Ullevål, Oslo, Norway

5 Department of Oncology, Sykehuset Innlandet, Gjøvik, Norway

6 Department of Oncology, University Hospital Northern Norway, Tromsø, Norway and Department of Clinical Medicine, University of Tromsø, Tromsø, Norway

7 Department of Oncology, Sørlandet Hospital, Kristiansand, Norway

8 Department of Oncology, Stavanger University Hospital, Stavanger, Norway

9 Department of Oncology, Ålesund Hospital, Ålesund, Norway

10 Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

11 Department of Oncology, Oslo University Hospital, Oslo, Norway and K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

For all author emails, please log on.

BMC Cancer 2012, 12:616  doi:10.1186/1471-2407-12-616

Published: 22 December 2012

Additional files

Additional file 1:

Figure S1. Number of DTCs detected in BM2-positive, docetaxel treated patients, at BM2, BM3 and BM4.

Format: PDF Size: 18KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data

Additional file 2:

Table S1. Complete DTC-status at all time points for BM2-positive patients.

Format: PDF Size: 36KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data

Additional file 3:

Table S2. Analyses of clinico-pathological data and DTC-status after treatment for patients with ≥ 3 DTCs at BM2.

Format: PDF Size: 26KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data

Additional file 4:

Table S3. Presentation of DTC status (at all performed time points), endocrine treatment and trastuzumab treatment status for BM1 and/or BM2 positive patients.

Format: PDF Size: 36KB Download file

This file can be viewed with: Adobe Acrobat Reader

Open Data